OFEV (nintedanib), inhibitor of tyrosine kinases

• OFEV has a Marketing Authorisation in the treatment of idiopathic pulmonary fibrosis (IPF).
• Its efficacy has been demonstrated versus placebo in terms of improvement in predicted forced vital capacity (FVC): the level of the effect is moderate and reservations have been expressed in respect of the demonstration of its efficacy in relation to mortality, given the numerous methodological limitations.
• It provides a minor improvement only in patients with an FVC ≥ 50% and a diffusing capacity for carbon monoxide (DLco) ≥ 30%.

-